Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues

@article{Hawse2019OptimizedID,
  title={Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues},
  author={John R. Hawse and Jodi M. Carter and Kirsten G. M. Aspros and Elizabeth S. Bruinsma and Justin W. Koepplin and Vivian Negron and Malayannan Subramaniam and James N. Ingle and Karen L. Rech and Matthew P. Goetz},
  journal={Breast Cancer Research and Treatment},
  year={2019},
  volume={179},
  pages={241-249}
}
Purpose Significant controversy exists regarding the expression patterns of estrogen receptor beta (ERβ) in normal and diseased breast tissue. To address this issue, we have validated two ERβ antibodies, optimized the IHC protocols for both antibodies and now report the expression patterns of ERβ in normal and malignant breast tissues. Methods ERβ antibody specificity was determined using western blot and IHC analysis. ERβ protein expression patterns were assessed via IHC in normal breast… 
The Prognostic Value of Estrogen Receptor β Isoform With Correlation of Estrogen Receptor α Among Sudanese Breast Cancer Patients
TLDR
It is concluded that ERβ was commonly expressed among Sudanese patients with breast cancer, either co-expressed with ERα or expressed alone, and in the ERα-negative subgroup, it was associated with better tumor outcomes suggesting ERβ should be included in the diagnostic protocol as an independent marker for favorable prognosis.
The prevalence and prognostic significance of estrogen receptor beta expression in non-small cell lung cancer.
TLDR
Improved detection and analysis techniques suggest that subcellular localization of ERβ, but not absolute expression, is a prognostic factor in NSCLC.
Applicability of Anti-Human Estrogen Receptor β Antibody PPZ0506 for the Immunodetection of Rodent Estrogen Receptor β Proteins
TLDR
The applicability of PPZ0506 for rodent ERβ studies is confirmed, and the results provide a fundamental basis for further examination of ERβ functions.
Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer
TLDR
Estrogen receptor beta was barely detectable in TNBC cell lines, but its upregulation reduced survivin, increased tumor suppressor expression, and suppressed proliferation, migration and invasion in both ligand-independent and dependent manners, suggesting the possible translational benefit of ERβ ligands.
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
TLDR
The results indicate that ESR2 is generally expressed at low levels in breast cancer but associated with improved overall survival and may be related to immune response modulation.
Estrogen Actions in Triple-Negative Breast Cancer
TLDR
The role of ERβ and GPER-1 as mediators of E2 action in TNBC as well as the function of ERRs as activators and modulators of estrogen signaling in this cancer entity are discussed.
The role of estrogen receptor beta in breast cancer
TLDR
This review summarizes available evidence regarding the involvement of ERβ in the clinical treatment and prognosis of breast cancer and describes signaling pathways associated with ERβ to highlight the potential of ER β as a therapeutic target.
Estrogen receptor β in cancer: to β(e) or not to β(e)?
TLDR
While ERβ exhibits anti-tumor activity in breast, ovarian, and prostate cancer, its expression is associated with disease progression and worse prognosis in lung cancer.
Estrogen Receptor β-Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer
TLDR
The capacity of ERβ to elicit anti-metastatic effects in highly aggressive Inflammatory breast cancer is demonstrated and ERβ and the identified associated genes as potential therapeutic targets in this disease are proposed.
...
...

References

SHOWING 1-10 OF 97 REFERENCES
Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody
TLDR
Evidence is provided that much of the controversy in the field with regard to the biological relevance of ERβ in breast cancer may be explained by variability in antibody sensitivity and specificity and the use of the MC10 antibody, in combination with highly specific antibodies targeting only full‐length ERβ, is likely to provide additional discriminatory features in breast cancers.
Clinical value of the wild-type estrogen receptor beta expression in breast cancer.
TLDR
The possibility that wild-type ERbeta protein expression could be used as a good prognostic indicator for breast cancer is demonstrated, with a significant correlation with ERalpha-EIA.
Clinical significance of the expression of estrogen receptors α and β for endocrine therapy of breast cancer
TLDR
A significant correlation between ERα EIA and IHC was seen and this indicates that this cut-off level of ERα IHC can be adopted to quantify breast cancer prognoses, and tumors with positive expression of ERβ wild-type tended to have a better response to endocrine therapy than negative ones.
Insufficient antibody validation challenges oestrogen receptor beta research
TLDR
A rigorous validation of 13 anti-ERβ antibodies concludes that only one antibody, the rarely used monoclonal PPZ0506, specifically targets ERβ in immunohistochemistry, highlighting how inadequately validated antibodies can lead an exciting field astray.
Expression of wild‐type estrogen receptor β protein in human breast cancer: Specific correlation with HER2/neu overexpression
TLDR
Clinical significances of ERβwt expression in human breast cancer patients may be more complex, and according to multivariate logistic regression analysis the most significant association was between ER βwt expression and HER2/neu overexpression.
Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas
TLDR
A need to understand the role and regulation of ERβ in normal breast and the reason for its down‐regulation in mammary carcinogenesis is indicated.
Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
TLDR
A significant correlation between ERalpha EIA and IHC was seen, which indicates that this cut-off level of ERalpha IHC can be adopted to quantify breast cancer prognoses, and tumors with positive expression of ERbeta wild-type tended to have a better response to endocrine therapy than negative ones.
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
  • N. Honma, R. Horii, G. Sakamoto
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
Immunohistochemical examination of ER-beta1 in addition to ER-alpha and PR is clinically important in patients with breast cancer treated with tamoxifen monotherapy, and positively staining for ER- betaN or ER-Beta1 was associated with significantly better survival.
...
...